Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad


Collapse Overview 
Collapse sponsor award id
IMA901


Collapse Biography 

Collapse Time 
Collapse start date
2012-04-12

Collapse end date
2014-07-31